Results 221 to 230 of about 13,428 (249)

<i>Nakaseomyces glabratus</i> drug resistance genes expression in vulvovaginal candidiasis: a systematic review. [PDF]

open access: yesCurr Med Mycol
Ranjbar Golafshani FZ   +4 more
europepmc   +1 more source

Bioprospecting, Synergistic Antifungal and Toxicological Aspects of the Hydroxychalcones and Their Association with Azole Derivates against Candida spp. for Treating Vulvovaginal Candidiasis. [PDF]

open access: yesPharmaceutics
Fernandes LS   +10 more
europepmc   +1 more source

Candida tropicalis clinical isolates: biofilm composition and architecture [PDF]

open access: yes, 2008
Azeredo, Joana   +4 more
core  
Some of the next articles are maybe not open access.

Related searches:

Recurrent vulvovaginal candidiasis

BMJ, 2020
### What you need to know A 22 year old woman asks your advice for treating recurrent thrush. She has self managed with over-the-counter treatments eight times in the past six months. She is frustrated and wants to know why it keeps coming back. Recurrent vulvovaginal candidiasis (RVVC) is a common problem, with an estimated prevalence of 9% in ...
Inna Vardi-Flynn   +2 more
openaire   +3 more sources

Biofilms and vulvovaginal candidiasis

Colloids and Surfaces B: Biointerfaces, 2019
Candida species, including C. albicans, are part of the mucosal flora of most healthy women, and inhabit the gastrointestinal and genitourinary tracts. Under favourable conditions, they can colonize the vulvovaginal mucosa, giving rise to symptomatic vulvovaginal candidiasis (VVC). The mechanism by which Candida spp.
Rodríguez-Cerdeira, Carmen   +9 more
openaire   +4 more sources

Vulvovaginal Candidiasis in Pregnancy

Current Infectious Disease Reports, 2015
Prevalence studies indicate that Candida species colonize the vagina in at least 20 % of all women, rising to 30 % in pregnancy. Although, some studies concluded that pregnant women were more likely to have symptomatic vaginal infections caused by Candida, yet other studies found a high prevalence of asymptomatic infection only during pregnancy.
T. J. Aguin, Jack D. Sobel
openaire   +3 more sources

Recurrent vulvovaginal candidiasis

Annals of Epidemiology, 2017
Recurrent vulvovaginal candidiasis (RVVC), multiple episodes of vulvovaginal candidiasis (VVC; vaginal yeast infection) within a 12-month period, adversely affects quality of life, mental health, and sexual activity. Diagnosis is not straightforward, as VVC is defined by the combination of often nonspecific vaginal symptoms and the presence of yeast ...
Freida Blostein   +3 more
openaire   +3 more sources

Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis

Annals of Pharmacotherapy, 2022
Objective To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC). Data Sources Literature was sought using PubMed (1966—February 2022) and EMBASE (1973—February 2022), and clinicaltrials.gov. Search terms included ibrexafungerp, SCY-078, and VVC.
Kylie N. Barnes   +2 more
openaire   +2 more sources

Chronic Vulvovaginal Candidiasis

New England Journal of Medicine, 2004
Vulvovaginal symptoms are common, and they represent one of the most frequent reasons for visits to physicians by women in all age groups. Vulvovaginitis is rarely life-threatening, and it is therefore vastly understudied and poorly understood. However, it is associated with substantial, albeit poorly quantified, cumulative morbidity. It causes genital
openaire   +5 more sources

Home - About - Disclaimer - Privacy